A Phase 2/3 interventional study of Valsartan and Placebo in Atrial Functional Mitral Regurgitation, sponsored by Jonathan Beaudoin. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Jonathan Beaudoin · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Mitral Valve Insufficiency with a site in Canada — 10 open to participants now, 23 under way, 1 of them phase 3. Mitral Valve Insufficiency · Canada.
Among the 47 studies in Mitral Valve Insufficiency with a site in Canada, this one is the 26th largest by planned enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 2/3, reaches primary completion later than 17 of the 22 other live ones, and was the 47th registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →10 of the 47 studies in Mitral Valve Insufficiency with a site in Canada are open now. Recruiting first, the newest first:
Vesalius Cardiovascular Inc. · Sites in Canada
Ages 19+
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
4C Medical Technologies, Inc. · Sites in Canada, United States, France and 4 more countries
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in Canada, United States
Ages 18+
Abbott Medical Devices · Sites in Canada, United States
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 4
First in 2006; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 69 across 280 interventional studies indexed under Mitral Valve Insufficiency.
Median enrollment 130 across the 35 interventional studies, 404 across the 12 observational. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 47 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Jonathan Beaudoin as lead sponsor.
Jonathan Beaudoin has 1 study filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
7 of the studies in Mitral Valve Insufficiency with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06816888Ottawa Heart Institute Research CorporationImpact of Automatic Prompts in Echocardiographic Reports on Referral to Cardiology | 2026-12-01 |
| NCT05061004Abbott Medical DevicesCephea Early Feasibility Study | 2026-12-31 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT03242642Medtronic CardiovascularTranscatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. | 2027-06 |
| NCT03066050Icahn School of Medicine at Mount SinaiLong Term Follow Up for CTSN Mitral Valve Repair Studies | 2027-07-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 47 studies in Mitral Valve Insufficiency with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether valsartan can slow the progression of atrial functional mitral regurgitation (AFMR) in adults with preserved left ventricular ejection fraction. The study will also evaluate the safety and tolerability of valsartan in this population.
The main questions it aims to answer are:
Researchers will compare valsartan to a placebo (a look-alike substance with no active drug) to see if valsartan reduces the progression of atrial functional mitral regurgitation and improves clinical and imaging outcomes.
Participants will:
Atrial functional mitral regurgitation (AFMR) is a common and increasingly recognized condition, particularly among older adults, women, patients with atrial fibrillation, and those with heart failure with preserved ejection fraction (HFpEF). AFMR is associated with significant morbidity and mortality, including recurrent hospitalizations and reduced quality of life. Current treatment options remain limited and are mainly focused on managing symptoms and associated conditions, with no therapy specifically targeting the underlying mechanisms of AFMR progression.
The pathophysiology of AFMR is characterized by left atrial dilation, which leads to stretching of the mitral annulus and inadequate leaflet adaptation in the absence of significant left ventricular dilation or systolic dysfunction. Although mitral valve leaflets have the capacity to adapt by increasing their surface area in response to annular dilation, this compensatory mechanism is often insufficient, resulting in progressive mitral regurgitation. Experimental and observational data suggest that activation of the renin-angiotensin-aldosterone system may contribute to maladaptive leaflet remodeling, fibrosis, and thickening.
Angiotensin receptor blockers (ARBs) have been shown in preclinical and observational studies to reduce fibrosis and promote more favorable tissue remodeling in cardiac structures, including valvular tissue. However, the potential role of ARBs in slowing the progression of AFMR has not been specifically evaluated in a randomized clinical trial. Valsartan, a commonly used ARB, may promote more adequate mitral leaflet adaptation and reduce structural maladaptive changes, thereby limiting AFMR progression.
The VALORIA study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of valsartan on the progression of AFMR.
The study will enroll 50 adult participants with at least moderate atrial functional mitral regurgitation, a left ventricular ejection fraction of 50% or greater, and no current indication for treatment with angiotensin-converting enzyme inhibitors or ARBs.
Participants will be randomized in a 1:1 ratio to receive either valsartan or placebo for a total duration of 12 months.
Participants assigned to the active treatment arm will receive valsartan at an initial dose of 40 mg twice daily, with planned titration up to a maximum of 160 mg twice daily based on tolerance, blood pressure, renal function, and potassium levels. Participants in the placebo group will follow an identical dosing and titration schedule. Dose adjustments will be guided by a standardized follow-up algorithm and predefined safety criteria, including hypotension, worsening renal function, or hyperkalemia.
All participants will undergo a comprehensive clinical and imaging evaluation at baseline. Three-dimensional transthoracic echocardiography will be performed at baseline, 6 months, and 12 months to assess mitral regurgitation severity, mitral annular geometry, and mitral leaflet morphology. Functional capacity will be evaluated using the 6-minute walk test at baseline and at 12 months. Health-related quality of life will be assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, 6 months, and 12 months.
Blood pressure will be monitored regularly throughout the study, including 24-hour ambulatory blood pressure monitoring at 1 month. Safety assessments will include a telephone follow-up at 7 days after treatment initiation, laboratory testing (serum creatinine and electrolytes) at 1 month, and additional blood pressure measurements after each dose adjustment.
The primary objective of the VALORIA study is to determine whether treatment with valsartan reduces the progression of atrial functional mitral regurgitation compared with placebo over a 12-month period. Secondary objectives include evaluating the effects of valsartan on mitral valve leaflet remodeling, cardiac structure and function, exercise capacity, and quality of life, as well as assessing the safety and tolerability of valsartan in this patient population.
By specifically targeting the structural mechanisms underlying AFMR, the VALORIA study aims to provide novel evidence to support a disease-modifying pharmacologic approach for this common and clinically significant condition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Valsartan 40 mg/tablet twice daily. . Titration up to 160 mg twice daily based on tolerance, blood pressure and renal function.
Drug: Valsartan
Placebo twice daily
Drug: Placebo
Valsartan 40 mg/tablet twice daily vs placebo. Titration up to 160 mg twice daily based on tolerance, blood pressure and renal function.
Placebo that looks like valsartan (caps)
Mitral leaflet size
Mitral leaflet size (cm2) by 3D echo and its variation vs baseline.
Time frame: Baseline VS 12 months
MR progression
MR progression measured by imaging (3D echocardiography). Mitral regurgitation is graded on a scale of I-IV (grade I (mild MR), grade II (moderate MR), grade III (moderate-to-severe MR) and grade IV (severe MR)). A higher mitral regurgitation grade is generally associated with a worse outcome for the patient.
Time frame: MR grade at 12 months follow-up vs baseline
Left ventricular volume
Left ventricular volume (mL) measured by imaging (3D echocardiography)
Time frame: baseline VS 12 months follow-up
Left ventricular function
Left ventricular function (% ejection fraction) measured by imaging (3D echocardiography)
Time frame: baseline VS 12 months follow-up
Pulmonary artery pressure
Pulmonary artery pressure measured by echocardiography (mmHg).
Time frame: baseline VS 12 months follow-up
Left atrial volume
Left atrial volume (ml) measured by echocardiography
Time frame: Baseline VS 12 months follow-up
Mitral thickness
Mitral thickness (mm) measured by echocardiography
Time frame: Baseline VS 12 months follow-up
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for May 2029, 33 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valsartan